Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences

Matthew M. Molusky,* Joanne Hsieh, Samuel X. Lee, Rajasekhar Ramakrishnan, Liana Tascau, Rebecca A. Haeusler, Domenico Accili, Alan R. Tall

Objective—The mechanisms underlying the cardiovascular benefit of the anti-diabetic drug metformin are poorly understood. Recent studies have suggested metformin may upregulate macrophage reverse cholesterol transport. The final steps of reverse cholesterol transport are mediated by the sterol transporters, ABCG5 (ATP-binding cassette transporter G5) and ABCG8 (ATP-binding cassette transporter G8), which facilitate hepatobiliary transport of cholesterol. This study was undertaken to assess the possibility that metformin induces Abcg5 and Abcg8 expression in liver and to elucidate the underlying mechanisms.

Approach and Results—Metformin-treated mouse or human primary hepatocytes showed increased expression of Abcg5/8 and the bile salt export pump, Bsep. Administration of metformin to Western-type diet–fed mice showed significant upregulation of Abcg5/8 and Bsep. This resulted in increased initial clearance of 3H-cholesteryl ester HDL (high-density lipoprotein) from plasma. However, fecal 3H-cholesterol output was only marginally increased, possibly reflecting increased hepatic Ldlr (low-density lipoprotein receptor) expression, which would increase nonradiolabeled cholesterol uptake. Abcg5/8 undergo strong circadian variation. Available chromatin immunoprecipitation-Seq data suggested multiple binding sites for Period 2, a transcriptional repressor, within the Abcg5/8 locus. Addition of AMPK (5′ adenosine monophosphate-activated protein kinase) agonists decreased Period 2 occupancy, suggesting derepression of Abcg5/8. Inhibition of ATP citrate lyase, which generates acetyl-CoA from citrate, also decreased Period 2 occupancy, with concomitant upregulation of Abcg5/8. This suggests a mechanistic link between feeding-induced acetyl-CoA production and decreased cholesterol excretion via Period 2, resulting in inhibition of Abcg5/8 expression.

Conclusions—Our findings provide partial support for the concept that metformin may provide cardiovascular benefit via increased reverse cholesterol transport but also indicate increased Ldlr expression as a potential additional mechanism. AMPK activation or ATP citrate lyase inhibition may mediate antiatherogenic effects through increased ABCG5/8 expression.

Visual Overview—An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2018;38:1493-1503. DOI: 10.1161/ATVBAHA.118.311212.)

Key Words: ATP-binding cassette transporter ■ cholesterol ■ high-density lipoprotein ■ metformin ■ sterol cardiovascular disease

Metformin, the most widely used drug to treat diabetes mellitus, seems to offer moderate protection against atherosclerotic cardiovascular disease.1,2 The mechanism of this likely benefit is poorly understood. In metabolic studies, diabetics treated with metformin had a significantly lower VLDL (very low–density lipoprotein) cholesterol level in the postprandial state.3 However, metformin treatment has not been consistently associated with changes in VLDL/LDL (low-density lipoprotein) cholesterol levels in population studies.1,2,4 Thus, the mechanisms underlying its apparent cardiovascular benefit are unclear.5 Recent studies have shown that metformin increases HDL (high-density lipoprotein)-mediated reverse cholesterol transport (RCT), acting on macrophages to upregulate Abca1/g1 which mediate the efflux of cholesterol onto and apoA-1 and HDL particles.6 The final step in the RCT pathway is mediated by the sterol transporters ABCG5 (ATP-binding cassette transporter G5) and ABCG8 (ATP-binding cassette transporter G8),7–9 which reside on the canicular membrane of hepatocytes facilitating excretion of cholesterol and plant sterols into bile. Genome-wide association studies have identified SNPs (single nucleotide polymorphisms) in the ABCG5/8
locus associated with LDL cholesterol levels, total cholesterol levels, and coronary artery disease.\textsuperscript{10–13} Abcg5/8 are known to be transcriptionally upregulated by the liver X receptor alpha (LXR\_\alpha, \textit{Nr1h3}) and by FoxO (Forkhead box O) transcription factors.\textsuperscript{14–17} However, other modes of regulation, including by metformin, have not been well documented. In this study, we sought to determine whether the final step of RCT mediated by Abcg5/8 might also be upregulated by metformin. This led to the discovery that Period 2 (PER2), a circadian regulator, binds and represses \textit{Abcg5/8} mRNA expression. PER2 in turn seems to be oppositely regulated by the activities of AMPK (5′-adenosine monophosphate-activated protein kinase) and ATP citrate lyase (ACLY). These findings provide a mechanism to explain how biliary cholesterol excretion is linked to hepatic lipogenic activity and the circadian cycle.

### Materials and Methods

The data that support the findings of this study are available from the corresponding author on reasonable request.

#### Mice and In Vivo Experiments

We chose to use male mice for our studies as it has been previously reported in rodents that glucose tolerance and plasma insulin concentrations vary during the estrous cycle.\textsuperscript{18} C57BL/6J mice were purchased from Jackson Laboratory (Stock No. 000664).\textsuperscript{19} Albumin-Cre were purchased from Jackson Laboratory (Stock No. 003574)\textsuperscript{20} and bred with Prkaa1 (protein kinase AMP-activated catalytic subunit alpha 1) flox/flox mice also purchased from Jackson Laboratory (Stock No. 014141)\textsuperscript{21} to produce mice with Prkaa1 knocked-out in liver (Alb-Cre\textsuperscript{+}/Prkaa1\_f/f and Alb-Cre\textsuperscript{+}/Prkaa1\_f/f). For chow fasting/refeeding model, C57Bl/6J mice were used. Mice were fasted for 14 hours, and then subsequently refed after injection with metformin (250 mg/kg) or saline control. After 4 hours of refeeding, mice were euthanized, and liver was collected and snap frozen in liquid nitrogen. For chronic metformin treatment, C57Bl6/J mice were fed a western-type diet (WTD; 42% calories from fat, 0.2% cholesterol, Envigo: TD:88132) for 3 months. Subsequently mice were split into 2 groups, one group receiving 250 mg/kg metformin or saline control (IP), daily, for 2 weeks. Mice were then euthanized in the fed state and livers were collected and snap frozen in liquid nitrogen and stored at −80°C. All protocols were approved by the Institutional Animal Care and Use Committee of Columbia University.

#### Primary Hepatocytes

Mouse hepatocytes were isolated using the Worthington Biochemical Corporation Hepatocyte Isolation Kit. In brief, mice were euthanized, and the livers were perfused with Hanks’ Balanced Salt solution, without calcium or magnesium. After perfusion, livers were switched to digestion media (L-15/MOPS solution) containing collagenase-elastase enzyme, supplemented with DNaseI. After digestion, livers were removed and placed on a 10 cm plate and minced with 1 mL further of digestion media and placed at 37°C for 5 minutes. After incubation, cells were washed in excess Leibowitz Media containing 10% FBS and spun at 300g for 3 min. Cell pellet was subsequently washed 2× with Leibowitz buffer containing 0.2% FBS and 0.5% BSA. Cells were counted and seeded at a density of 3.0×10^6 cells per well of a six-well plate in DMEM (0.2% FBS, 0.5% BSA). Forty-five minutes after plating, cells were washed with PBS, and new media (DMEM+0.2%FBS+0.5%BSA) was added containing AMPK activators or ACLY inhibitor as described in text. Phospho-ACC1 (acetyl-CoA carboxylase 1; Ser79) antibody was obtained from Cell Signaling (Clone D7D11).

#### RNA Isolation, cDNA, and Real-Time Quantitative Polymerase Chain Reaction

RNA was isolated using TriZol Reagent (Ambion) which was then combined with Zymogen RNA isolation kit (Quick-RNA Miniprep). RNA was quantified using a NanoDrop 8000 Spectrophotometer (ThermoFisher). Five hundred nanogram of RNA was then used to synthesize cDNA using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). cDNA was then diluted 10-fold for real-time quantitative polymerase chain reaction (PCR) analysis. Gene expression analysis was performed using a Step One Plus Real Time PCR system (Applied Biosciences). Fold change in gene expression was calculated using the \textDelta\textDeltaCt method. Real-time PCR primer sequences for mouse genes are as follows: \textit{Rplp0}, 5′-gaaatgtgctctcattacgg, 3′-3gtggcccagctacccacagg; \textit{Abcg5}, 5′-atccaaaccctatgaatacg; 3′-tacatttgaggccagctgct; \textit{Abcg8}, 5′-tctacttgctttctcttggg; 3′-attg acctcctgaggtac; bile salt export pump (\textit{Bsep}), 5′-tctgagctagt gattctgga; 3′-3ccataaacactgcttgat. Human real-time PCR primer sequences are as follows: \textit{CYCLOA}, 5′-gcatcacaaccactcg; 3′-atgtg tcaggtgtggtcct; \textit{ACLY}, 5′-tctgaggtggtggtcct; 3′-3aggg aaagacctgg; \textit{BSEP}, 5′-ggaacccggaatcttac; 3′-atgtg aaagacctgg; \textit{PER2}, 5′-tggattgagtttggaag; 3′-3ccataaacactgcttgat. For chow fasting/refeeding model, C57Bl/6J mice were used. Mice were fasted for 14 hours, and then subsequently refed after injection with metformin (250 mg/kg) or saline control. After 4 hours of refeeding, mice were euthanized, and liver was collected and snap frozen in liquid nitrogen. For chronic metformin treatment, C57Bl6/J mice were fed a western-type diet (WTD; 42% calories from fat, 0.2% cholesterol, Envigo: TD:88132) for 3 months. Subsequently mice were split into 2 groups, one group receiving 250 mg/kg metformin or saline control (IP), daily, for 2 weeks. Mice were then euthanized in the fed state and livers were collected and snap frozen in liquid nitrogen and stored at −80°C. All protocols were approved by the Institutional Animal Care and Use Committee of Columbia University.

#### Primary Hepatocytes

Mouse hepatocytes were isolated using the Worthington Biochemical Corporation Hepatocyte Isolation Kit. In brief, mice were euthanized, and the livers were perfused with Hanks’ Balanced Salt solution, without calcium or magnesium. After perfusion, livers were switched to digestion media (L-15/MOPS solution) containing collagenase-elastase enzyme, supplemented with DNaseI. After digestion, livers were removed and placed on a 10 cm plate and minced with 1 mL further of digestion media and placed at 37°C for 5 minutes. After incubation, cells were washed in excess Leibowitz Media containing 10% FBS and spun at 300g for 3 min. Cell pellet was subsequently washed 2× with Leibowitz buffer containing 0.2% FBS and 0.5% BSA. Cells were counted and seeded at a density of 3.0×10^6 cells per well of a six-well plate in DMEM (0.2% FBS, 0.5% BSA). Forty-five minutes after plating, cells were washed with PBS, and new media (DMEM+0.2%FBS+0.5%BSA) was added containing AMPK activators or ACLY inhibitor as described in text. Phospho-ACC1 (acetyl-CoA carboxylase 1; Ser79) antibody was obtained from Cell Signaling (Clone D7D11).

#### RNA Isolation, cDNA, and Real-Time Quantitative Polymerase Chain Reaction

RNA was isolated using TriZol Reagent (Ambion) which was then combined with Zymogen RNA isolation kit (Quick-RNA Miniprep). RNA was quantified using a NanoDrop 8000 Spectrophotometer (ThermoFisher). Five hundred nanogram of RNA was then used to synthesize cDNA using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). cDNA was then diluted 10-fold for real-time quantitative polymerase chain reaction (PCR) analysis. Gene expression analysis was performed using a Step One Plus Real Time PCR system (Applied Biosciences). Fold change in gene expression was calculated using the \textDelta\textDeltaCt method. Real-time PCR primer sequences for mouse genes are as follows: \textit{Rplp0}, 5′-gaaatgtgctctcattacgg, 3′-3gtggcccagctacccacagg; \textit{Abcg5}, 5′-atccaaaccctatgaatacg; 3′-tacatttgaggccagctgct; \textit{Abcg8}, 5′-tctacttgctttctcttggg; 3′-attg acctcctgaggtac; bile salt export pump (\textit{Bsep}), 5′-tctgagctagt gattctgga; 3′-3ccataaacactgcttgat. Human real-time PCR primer sequences are as follows: \textit{CYCLOA}, 5′-gcatcacaaccactcg; 3′-atgtg tcaggtgtggtcct; \textit{ACLY}, 5′-tctgaggtggtggtcct; 3′-3aggg aaagacctgg; \textit{BSEP}, 5′-ggaacccggaatcttac; 3′-atgtg aaagacctgg; \textit{PER2}, 5′-tggattgagtttggaag; 3′-3ccataaacactgcttgat. For chow fasting/refeeding model, C57Bl/6J mice were used. Mice were fasted for 14 hours, and then subsequently refed after injection with metformin (250 mg/kg) or saline control. After 4 hours of refeeding, mice were euthanized, and liver was collected and snap frozen in liquid nitrogen. For chronic metformin treatment, C57Bl6/J mice were fed a western-type diet (WTD; 42% calories from fat, 0.2% cholesterol, Envigo: TD:88132) for 3 months. Subsequently mice were split into 2 groups, one group receiving 250 mg/kg metformin or saline control (IP), daily, for 2 weeks. Mice were then euthanized in the fed state and
nuclei were spun at 1500 rpm for 8 min and resuspended in 200 μL of micrococcal nuclease reaction buffer (20 mMol/L Tris-HCl [pH 8.0], 1% Triton-X100, 0.1% IGEPAL, 137 mMol/L NaCl). For PER2 (Alpha Diagnostic International, PER2-A1) and cryptochrome 1 (CRY1; Alpha Diagnostic International, CRY11-A) pull down, cells were initially cross-linked with Di-(N-succinimidyl) glutarate (DSS, CovAChem; PBS, 12% DMSO) for 30 min at room temperature. Hepatocytes were washed with PBS and cross-linked with 1% formaldehyde for 15 min at room temperature and quenched and processed as described earlier. Crude nuclei were then digested with micrococcal nuclease (New England Biolabs, M0247S) at 37°C to produce DNA fragments between 1 and 4 histone lengths (≈100–500 bp). Reactions were stopped by addition of excess EDTA (10 mMol/L final concentration). Samples were sonicated twice using a Fisher Scientific Sonic Dismembrator (Model FB120) at 40% amplitude for 15 s (30 s rest). Lysates were spun at 13200 rpm for 2 min to remove insoluble fraction. Protein quantification of lysate was performed using a BCA Protein Assay Kit (Pierce). Forty microgram of protein was used for RNA Pol II and H3K4me3 pull down, while PER2 and CRY1 pull down was performed with 400 μg of protein. IP reactions were diluted to 1 mL in M奈ase buffer (1 mMol/L PMSF, 1 mMol/L EDTA, Halt Protease and Phosphatase inhibitors). Lysates were cleared with Protein G Dynabeads (Invitrogen) for 1 hour at 4°C, after which time Dynabeads were removed (2.5% was removed for input), and 1 μg of anti-H3K4me3, 1 μg anti-RNA Pol II, 5 μg anti-PER2, or 5 μg anti-CRY1 were added to corresponding tubes along with IgG to control tubes. Immunoprecipitations were allowed to rotate overnight at 4°C. After overnight incubation, 30 μL of Protein G Dynabeads were added to each tube and allowed to incubate for another 2 hours. Dynabeads were separated by using a DynaMag-2 (Invitrogen) magnet. Dynabeads were washed 2× with M奈ase Buffer, Wash Buffer 2 (20 mMol/L Tris-HCl [pH 8.0], 1% Triton-X100, 0.1% SDS, 500 mMol/L NaCl, 2 mMol/L EDTA), Wash Buffer 3 (20 mMol/L Tris-HCl [pH 8.0], 1% Triton-X100, 250 mMol/L LiCl, 2 mMol/L EDTA), and 1× with TE buffer (10 mMol/L Tris-HCl, 1 mMol/L EDTA).

To elute bound DNA, Dynabeads were resuspended in 100 μL of SDS elution buffer (50 mMol/L NaHCO3, 1% SDS) and agitated for 15 min at room temperature. Supernatant was separated from beads using a magnet and placed in a new tube. A second elution was performed with 100 μL of elution buffer and incubated at 55°C for 15 min. Supernatant was then separated from beads using a magnetic stand and added to each sample. NaCl was added to each sample to a final concentration of 250 mMol/L and incubated at 65°C overnight to reverse cross-link. Samples were then treated with RNAseA (10 μg/ sample, 1 hour, 37°C) and then digested with Proteinase K (80 μg/ sample, 55°C, 2 hours). DNA was isolated using QuickPrep kits (Qiagen) and eluted in ddH2O. Isolated DNA was stored at −80°C.

Statistical Analysis
All values are reported as means±SD or SEM where indicated. Data were analyzed using Student’s t tests, unpaired t test with Welch’s correction, one-way analysis of variance, or 2-way analysis of variance with Tukey’s post hoc test where indicated. Tests were validated for normalcy using either D’Agostino & Pearson or Shapiro-Wilk normalcy tests, and variance was tested using the F test or Brown-Forsythe (analysis of variance). Statistical analysis was performed using Prism (GraphPad) software.

Results
Metformin Induces Abcg5 and Abcg8 in Primary Hepatocytes and Liver
We treated mouse primary hepatocytes with 0.5 mMol/L metformin for 20 hours and found a marked upregulation of both Abcg5 and Abcg8 mRNAs along with the bile salt transporter, Bsep (Abcb11) (Figure 1A). Because metformin indirectly activates AMPK through interactions with mitochondrial proteins,29 we sought to establish whether the upregulation of Abcg5/8 was because of direct activation of AMPK. To this end, we used the AMPK-specific agonist A-76966230 in primary hepatocytes and found that, in a dose-dependent manner, A-769662 was able to induce Abcg5 and Abcg8 mRNA (Figure 1B). We observed similar effects on expression of Abcg5, Abcg8, and Bsep in primary human hepatocytes treated with ACAR (5-aminooimidazole-4-carboxamido ribonucleotide; Figure 1C), suggesting a conserved pathway between mice and humans. The relative levels of Abcg5 and Abcg8 mRNA decrease rapidly after initial plating (data not shown); however, Ct values were still in the range of 29 to 32 for Abcg5 and Abcg8 in our primary hepatocyte culture experiments (Table I in the online-only Data Supplement).

Previous work has established the hormonal regulation of AMPK activity during fasting and feeding.31–34 Consistent with the cell culture results, we observed an increase in Abcg5/8 mRNA in fasting versus refeed livers (Figure 1D). We also used a fasted/refed rodent model to test metformin induction of Abcg5/8 in vivo. After a bolus of metformin, there was a modest but significant upregulation of Abcg5 and Abcg8 in the refed group (n=15) compared with a saline control.
AMPK activity has been shown to be downregulated in high-fat diet–fed mice, and therefore we sought to determine whether increasing AMPK signaling would upregulate ABCG5/8 more prominently after feeding such a diet. We fed C57BL6/J mice a Western-type diet (42% fat/cal, 0.2% cholesterol) for 3 months, then placed mice on metformin (250 mg/kg/d, intraperitoneal) or saline intraperitoneally for 2 weeks and then euthanized them in the fed state. Consistent with our primary hepatocyte data, metformin prominently induced the expression of ABCG5, ABCG8, and BSEP compared with the saline control (Figure 1F; \( P < 0.05 \)).

Mice carry 2 isoforms of the catalytic subunit of AMPK, \( \alpha_1, \alpha_2 \) (Prkaa1, Prkaa2), which are thought to be similarly expressed in liver; however, Prkaa1 has been shown to rhythmically localize to the nucleus which may aid in regulating transcriptional activity.\(^{37}\) To examine the AMPK dependence of metformin-induced expression of ABCG5/8, we bred Albumin-Cre (Alb-Cre) with Prkaa1 floxed mice (fl/fl). In the Prkaa1 knockout (Alb-Cre(+) Prkaa1 fl/fl) hepatocytes, there was a significant reduction in ABCG5/8 mRNAs after metformin treatment compared with floxed controls (Alb-Cre(−) Prkaa1 fl/fl) (Figure 1G through 1-I; \( P < 0.05 \)). This indicates that regulation of ABCG5/8 by metformin depends at least in part on intact AMPK signaling. The residual increase in ABCG5/8 expression in Alb-Cre(+) Prkaa1 fl/fl mice could reflect activity of Prkaa2 or an independent pathway, which has recently been demonstrated, where an AMPK \( \beta \)-specific subunit agonist induction of ABCG5/8 was abolished \( \alpha_1/\alpha_2 \) knockout livers.\(^{38}\)

**Induction of ABCG5/8 Expression Does Not Require LXR or FoxO Transcription Factors**

LXR\( \alpha \), the predominant isoform of LXR expressed in the liver,\(^{39-41}\) has been shown to mediate induction of ABCG5 and ABCG8 in response to feeding a high cholesterol diet.\(^{14}\) However, in primary hepatocytes lacking LXR\( \alpha \), the main
isoform of LXR expressed in the liver, there was no difference in the induction of Abcg5/8 compared with wild-type controls (Figure I in the online-only Data Supplement). In addition, the FoxO family of transcription factors has been shown to induce Abcg5/8, providing a link between hepatic insulin resistance and gallstone formation. However, the induction of Abcg5/8 was actually more pronounced in response to AMPK activators in FoxO triple knockout (FoxO1/3/4, FoxO TKO) hepatocytes (Figure IIA and IIB in the online-only Data Supplement), indicating involvement of an alternative regulatory pathway. FoxO TKO hepatocytes did show reduced induction of Bsep when treated with AICAR compared with wild-type controls (Figure IIC in the online-only Data Supplement), consistent with previous reports.

AMPK Activation Increases Abcg5/8 Transcriptional Activity
To determine if AMPK activators require new transcription to induce Abcg5/8 expression in primary hepatocytes, we treated cells with the transcription inhibitor actinomycin D in the presence or absence of AICAR. Interestingly, we found that actinomycin D alone was able to induce Abcg5/8 mRNA and that addition of AICAR had no further additive effect (Figure 2A). Moreover, inhibiting protein synthesis using CHX (cycloheximide) resulted in increased expression of Abcg5/8, as well as Bsep, and again there was no additional effect of AICAR in the presence of CHX (Figure 2B). These observations suggested that Abcg5/8 gene expression might be repressed by a short-lived transcriptional inhibitor. Furthermore, we saw an increase in RNA Polymerase II binding at the Abcg5/8 promoter, indicating enhanced transcription (Figure 2C), and a significant elevation in H3K4me3 at the promoters of Abcg5/8 and Bsep, an epigenetic mark suggesting more transcriptionally active chromatin at the Abcg5/8 locus (Figure 2D). Together these results indicate that AMPK activation increases transcription at the Abcg5/8 and Bsep loci, possibly via inhibition of the activity of a short-lived transcriptional repressor.

Binding of PER2 to the Abcg5/8 Locus Is Decreased by AMPK Activation
Many hepatic genes involved in metabolic processes are regulated in a circadian pattern. Mining microarray datasets, we observed a strong rhythmicity of Abcg5/8 with suppression of expression during the dark phase (Figure 2E), suggesting that the core circadian clock machinery could play a transcriptional regulatory role. Another core clock gene ChIP-seq database showed increased binding of Period 2, a repressor of transcription, over the Abcg8 promoter, paralleling the suppression of Abcg8 mRNA expression and Pol II binding during the dark phase with opposite findings during the light phase (Figure 2F).

AMPK signaling is known to decrease the stability of Period 2 indirectly through the action of a second kinase, CK1ε (casein kinase 1-epsilon) and also directly via phosphorylation of PER2 heterodimer partner, CRY1. PER2 protein levels are also rapidly decreased by CHX treatment, consistent with our data suggesting a short-lived transcriptional repressor (Figure 2B). We used a well characterized PER2 antibody against PER2, and performed ChIP on primary hepatocytes treated with vehicle, metformin or A-769662. Using primers designed within the bicistronic promoter shared by Abcg5 and Abcg8, we found no significant decrease in PER2 occupancy within the presence of metformin or A-769662 compared with vehicle control (Figure 3A). To validate the ChIP for PER2, we used published ChIP primers against a known PER2 target, Dbp, showing the expected decrease in PER2 binding within the Dbp upstream enhancer (Figure 3B). Additionally, CRY1 occupancy within the Abcg5/8 promoter was decreased in PER2−/− (P<0.01) on activation of AMPK (Figure 3C).

Metformin Increases Clearance of 3H-CE in Mice on a Western-Type Diet
Given the role of Abcg5/8 in reverse cholesterol transport, we next sought to test whether metformin treatment increased cholesterol secretion to feces. We placed mice on a Western-type diet and injected them with metformin (250 mg/kg/d, IP) for 2 weeks at the end of which we injected with HDL containing 3H-CE (intravenously). Three days before HDL injection, mice were given Ezetimibe (oral gavage, daily) to block cholesterol uptake via NPC1L1 in enterocytes. After injection, we took blood at 2, 4, 8, and 24 hours. Feces were also collected over a 2-day period of time, at which point mice were euthanized. Metformin-treated mice showed an increased rate of cholesterol clearance at 2 hours postinjection (Figure 4A; *P<0.05, two-way analysis of variance) compared with vehicle-treated mice. Using a 2-pool nonlinear model, we saw a significant increase in the initial clearance rate of 3H-CE (Figure 4B) in metformin-treated mice. We saw no difference in hepatic 3H-CE uptake (Figure IIIA in the online-only Data Supplement), while the fractional catabolic rate was similar between both groups (Figure IIIB in the online-only Data Supplement). The fractional flux to the side pool was also significantly increased in metformin-treated mice, while the turnover constant of the side pool remained similar between both groups (Figure IIIC and IIID in the online-only Data Supplement). However, while elevated, the excretion of 3H-cholesterol in feces was not significantly increased in metformin-treated mice (Figure 4C; P=0.20). One possible explanation for the latter finding could be an increase in uptake of LDL cholesterol in the liver of metformin-treated mice, decreasing the specific activity of hepatic 3H-cholesterol. There was a significant increase in Ldlr (low-density lipoprotein receptor) mRNA levels in WTD-fed mice treated with metformin (Figure IIIE in the online-only Data Supplement; *P<0.05). Another possibility is that metformin is increasing Abcg5/8 mRNA. However, there was no change in enterocyte Abcg5 or Abcg8 mRNA in metformin-treated mice (Figure IIIG in the online-only Data Supplement).

Inhibition of ACLY Induces Abcg5/8 Expression in Primary Hepatocytes
Given that PER2 is a transcriptional inhibitor of Abcg5/8 expression, and is opposed by AMPK activation, we sought additional evidence for a role of this pathway in the regulation of Abcg5/8 expression. PER2 is stabilized by the acetyl-CoA-driven acetylation of lysine residues, which inhibits
ubiquitin-driven proteasomal degradation.\textsuperscript{51} Acetyl-CoA can be generated from mitochondrial-derived citrate by ACY.\textsuperscript{52,53} It has been established in mice that PER2 protein is increased during the night phase of the circadian cycle\textsuperscript{51,54} corresponding to increased nutrient intake and increased acetyl-CoA generation. We therefore postulated that acetyl-CoA produced by ACY could affect PER2 acetylation, as well as stability, and therefore modulate the expression of \textit{Abcg5/8}. We used

![Figure 2. AMPK (5′ adenosine monophosphate-activated protein kinase) activation increases \textit{Abcg5/8} (ATP-binding cassette transporter G5/G8) transcriptional activity.](image)

**A**, Real-time quantitative polymerase chain reaction (PCR) analysis of \textit{Abcg5}, \textit{Abcg8}, and \textit{Bsep} expression in primary hepatocytes treated with actinomycin (ActD), with or without AICAR (5-aminimidazole-4-carboxamide ribonucleotide) for 6 hours. **B**, Real-time qPCR analysis of \textit{Abcg5}, \textit{Abcg8}, and \textit{Bsep} expression in primary hepatocytes treated with CHX (cycloheximide) with or without AICAR for 6 hours. **C**, RNA Pol II chromatin immunoprecipitation assay (ChIP) using primers against the \textit{Abcg5/8} bi-cistronic promoter. **D**, ChIP assay using either HSK4me3 antibody or IgG control in primary hepatocytes treated with CHX. Primers designed against the \textit{Abcg5/8} promoter and \textit{Bsep} promoter. **E**, Liver microarray data of \textit{Abcg5} and \textit{Abcg8} expression over 2 days from Hughes et al.\textsuperscript{43} **F**, Radial plot of relative amplitude of RNA Pol II binding (blue), PER2 binding to \textit{Abcg5/8} promoter, and \textit{Abcg8} mRNA (green) as described in Koike et al.\textsuperscript{44} A, B, and C, Data represents mean±SD; ***P<0.001 using 1-way analysis of variance (ANOVA) with Tukey’s post hoc test. C and D, Data represents mean±SD; *P<0.05, **P<0.01 using Student t test.

![Figure 3. Period 2 (PER2) and cryptochrome 1 (CRY1) have decreased binding at the \textit{Abcg5/8} (ATP-binding cassette transporter G5/G8) promoter when treated with AMPK (5′ adenosine monophosphate-activated protein kinase) activating compounds, metformin, or A-769662. Chromatin immunoprecipitation (ChIP) assay pulling down endogenous Per2 (**A** and **B**) or Cry1 (**C**) at the \textit{Abcg5/8} promoter (**A** and **C**) or at the proximal \textit{Dbp} promoter (**B**), a known PER2 binding locus.](image)

**A**, liver microarray data of \textit{Abcg5/8} expression over 2 days from Hughes et al.\textsuperscript{43} **B**, Data represents mean±SD; *P<0.05, **P<0.01 using Student t test.
the ACLY inhibitor BMS 303141 (referred to in figures as iACLY)\textsuperscript{55,56} to treat primary hepatocytes over a time course similar to that of metformin treatment. This resulted in a significant upregulation of \textit{Abcg5}, \textit{Abcg8}, and \textit{Bsep} in our primary hepatocyte model (Figure 5A), paralleled by a decreased occupancy of PER2 at the \textit{Abcg5/8} promoter (Figure 5B). There was also a significant decrease in PER2 binding at the \textit{Dbp} locus (Figure 5C), consistent with a modification of PER2 rather than a locus-specific effect. The regulation of \textit{Abcg5/8} by inhibition of ACLY does not require intact AMPK signaling, as \textit{Prkaa1} KO hepatocytes responded similarly to wild-type hepatocytes (Figure 5D). Additionally, inhibition of ACLY did not result in increased \textit{ACC1} (Ser79) phosphorylation, a known target of AMPK, compared with metformin treatment (Figure 5E). This suggests that ACLY is not acting upstream of AMPK to regulate \textit{Abcg5/8} expression, but rather is acting through a parallel pathway or downstream of AMPK activity.

ACLY Activity Regulates Stability of PER2

Because we observed decreased PER2 binding at the \textit{Abcg5/8} locus with ACLY inhibition, we sought additional evidence that ACLY regulates PER2 stability. Thus, we knocked down \textit{Acly} expression by siRNA (Figure 6A) in HEK293A cells

![Figure 5](attachment:figure5.png)

**Figure 5.** Inhibition of ATP citrate lyase (ACLY) results in the increase in \textit{Abcg5/8} (ATP-binding cassette transporter G5/G8) expression accompanying a reduction of period 2 (PER2) at \textit{Abcg5/8} promoter in primary hepatocytes. A, Real-time quantitative polymerase chain reaction (qPCR) analysis of \textit{Abcg5}, \textit{Abcg8}, and \textit{Bsep} in primary hepatocytes treated with ACLY inhibitor, BMS 303141 (8 \textmu mol/L), for 20 hours (n=3). B, Chromatin immunoprecipitation (ChIP) assay using endogenous Per2 antibody at the \textit{Abcg5/8} promoter or (C) \textit{Dbp} promoter in primary hepatocytes treated with DMSO or iACLY (n=3–4 pooled). D, Real-time ePCR analysis of \textit{Abcg5} and \textit{Abcg8} in primary hepatocytes from \textit{Prkaa1} wild-type (WT) and \textit{Prkaa1} knockout (KO) animals treated with ACLY inhibitor, BMS 303141 (8 \textmu mol/L) for 20 hours (n=3). E, Western blot of phosphorylation of ACC1 (acetyl-CoA carboxylase 1) at Ser 79 in cells treated with iACLY (8 \textmu mol/L) or metformin (0.5 mmol/L) for 20 hours. Data represents mean±SD. *P<0.05, **P<0.01 using unpaired Student \textit{t} test. B and C, Data represents mean±SD using ordinary 2-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (D).
expressing Flag-tagged PER2 and then treated cells with CHX (50 μg/mL). There was lower expression of PER2 protein at the 2-hour time point, suggesting that by limiting Acly we increased the turnover of PER2 (Figure 6B). Conversely, when we overexpressed a constitutively active form of ACLY, ACLY(S455D),27,28 we observed an increase in the overall levels of PER2, suggesting that increased production of acetyl-CoA increased PER2 stability (Figure 6C). Similarly, when we overexpressed ACLY(S455D) and Flag-tagged CRY1,26 we observed increased protein expression of CRY1 (Figure 6D). As CRY1 has not been shown to be acetylated, the increased protein levels of CRY1 could be because of increased endogenous PER2, which has been shown to block CRY1 interactions, the E3 ubiquitin ligases and subsequent proteasomal degradation.57–60

**Discussion**

Our studies in mice and in primary mouse and human hepatocytes indicate that metformin and AMPK activation induce expression of Abcg5 and Abcg8, complementing recent studies from the Steinberg laboratory showing that metformin increases macrophage RCT in mice by upregulating Abca1/g1 expression in macrophages.6 Given the strong link between ABCG5/8 expression and coronary artery disease in humans,11–13 this suggests a novel mechanism to explain the apparent benefit of metformin treatment in cardiovascular disease. AMPK activation was shown to decrease the binding of a circadian transcriptional repressor, PER2, at the Abcg5/8 promoter, providing a mechanism to explain increased Abcg5/8 expression (and biliary cholesterol excretion) during fasting/daytime in mice. These observations are consistent with rodent models of circadian cholesterol efflux to bile. In rats, maximum cholesterol secretion into bile occurs at or near the day to night transition, while maximum bile salt output occurs in the dark phase, slightly lagging behind cholesterol secretion.61 In humans with the opposite circadian rhythm, bile becomes supersaturated with cholesterol (lithogenic) during fasting at night, and cholesterol crystals become prominent in bile with diets involving prolonged fasting.62–65 Interestingly, similar increases in Abcg5/8 expression in association with decreased PER2 binding to the Abcg5/8 promoter were observed in response to ACLY inhibition. Our studies suggest that increased ACLY activity (eg, during feeding) results in increased acetylation of PER2, thereby decreasing the expression of Abcg5/8, while AMPK activation (during fasting and the light phase) promotes the degradation of CRY1 and PER2 and increases Abcg5/8 expression (Figure 6E).

These findings may provide an AMPK-coordinated mechanism underpinning the balance of cholesterol disposition in hepatocytes between esterification/secretion in VLDL versus excretion into bile. AMPK acts to decrease fatty acid biosynthesis and to increase fatty acid oxidation,32,66 decreasing cholesterol esterification. The upregulation of Abcg5/8 in fasting liver resulting from AMPK activation may then facilitate removal of excess cholesterol (ie, not being incorporated into VLDL particles or esterified with fatty acids into cholesterol esters) by excretion into bile. Similarly, inhibiting ACLY and therefore reducing de novo lipogenesis could result in an increase in Abcg5/8, which provides a mechanism to dispose of cholesterol by excretion. Additional transcriptional control of Abcg5/8 expression is known to be exerted via LXR and FOXO transcription factors. While the effects of AMPK activation were independent of LXR and FOXO1/3/4 in cultured cells, our studies indicate that AMPK activation decreases LXR and FOXO2/3 levels in cultured cells, which may explain why the effects of AMPK activation were independent of LXR and FOXO1/3/4 in cultured cells. 

---

**Figure 6.** ATP citrate lyase (ACLY) activity regulates stability of Period 2 (PER2). A, Real-time quantitative polymerase chain reaction (qPCR) analysis of Acly expression in HEK293A cells transfected with siRNA against Acly or control, nonspecific siRNA. B, HEK293A cells cotransfected with Flag-tagged mPER2 with control siRNA or Acly siRNA, which were then treated with 50 μg/mL CHX (cycloheximide) for 0, 2, or 6 hours. C and D, HEK293A cells cotransfected with Flag-tagged mPER2 (C) or Flag-tagged mCRY1 (D), with or without a constitutively active form of ACLY, ACLY(S455D). E, Schematic representation of opposite effects of AMPK (5′-adenosine monophosphate-activated protein kinase) and ACLY on PER2/CRY1 repressive effects on Abcg5/8 (ATP-binding cassette transporter G5/G8) mRNA. Data represents mean±SD; *P<0.05, using unpaired Student t test.
hepatocytes, the more pronounced effect of metformin on Abcg5/8 expression in mice fed the WTD could be related to an effect of LXRα to open chromatin at the locus, increasing access to PER2. During refeeding, decreased nuclear FOXO1 and suppression of AMPK activity would act in parallel to decrease Abcg5/8 expression. Metformin treatment in the insulin resistant states might be expected to increase insulin action, decreasing nuclear FOXO1 and opposing the effects of increased AMPK activity. However, because metformin increased hepatic Abcg5/8 expression in WTD-fed mice, the predominant effect of metformin is presumably exerted by the mechanisms described herein.

We show that activation of AMPK and inhibition of ACLY decrease Period 2 transcriptional inhibitory activity at the Abcg5/8 locus. AMPK has been shown to decrease the stability of PER2 via an indirect pathway, as well as PER2 binding partner CRY1 via phosphorylation-mediated degradation. These findings link the negative limb of the circadian clock to Abcg5/8 expression via PER2. The positive arm of the core circadian clock pathway involving BMAL1 has also been implicated in the regulation of Abcg5/8 and cholesterol efflux. Pan et al found that knockout of Bmal1, globally or in liver specifically, decreased Abcg5/8 expression and consequently decreased cholesterol secretion into bile and feces and increased atherosclerosis. This regulation was indirect as BMAL1 regulated another transcription factor, Gata4/6, that directly bound to the Abcg5/8 bicistronic promoter.

Metformin is a preferred initial treatment for type 2 diabetest mellitus in part because of an apparent benefit on atherosclerotic cardiovascular disease. The UKPDS Study (United Kingdom Prospective Diabetes Study) demonstrated that patients treated with metformin had a reduced risk of myocardial infarction, as well as decreased risk of diabetes mellitus–related deaths and all-cause mortality compared with a conventional therapy. Moreover, patients with a history of coronary artery disease showed a significant decrease in cardiovascular events compared with patients given another class of anti-diabetic drug, glipizide. Early studies with metformin showed a decrease in total cholesterol, LDL cholesterol, and triglyceride levels compared with control groups, in addition to increased HDL levels. However, more recent studies with a longer follow-up duration have not shown the same effects on lipoproteins. While human relevance is uncertain, our studies raise the possibility that the cardiovascular benefit of metformin could be explained in part by upregulation of Abcg5/8. Genetic ablation of Abcg5/8 in mice resulted in decreased biliary cholesterol and increased VLDL cholesterol levels. Conversely, transgenic overexpression of human Abcg5/8 in mice resulted in increased cholesterol excretion to bile, decreased VLDL/LDL cholesterol, and decreased atherosclerotic lesion size in LDLR-deficient mice, indicating an LDLR-independent mechanism of LDL reduction. Our findings provide partial support for the hypothesis that the beneficial effects of metformin may be explained by increased RCT. We tested the RCT hypothesis by injecting H-CE HDL into WTD-fed mice given daily injections of metformin. There was a significant increase in the initial rapid clearance of H-CE from plasma. However, there was only a trend for increased excretion of H-cholesterol in feces (P=0.20). This could be because the 2 day fecal collection introduced too much variability to detect a transient initial effect. Alternatively, the increased Ldlr expression in liver could increase the uptake of nonradiolabeled LDL cholesterol, decreasing the specific activity of the hepatic and fecal H-cholesterol pool. The increased Ldlr mRNA may have arisen from increased expression of Abcg5/8, as well as inhibition of HMGCoA (3-hydroxy-3-methylglutaryl-CoA) reductase by AMPK activation. Together the findings suggest that both LDL cholesterol lowering and increased RCT could represent benefits that accrue from metformin, AMPK activation, and ACLY inhibition via upregulation of Abcg5/8.

Targeting ACLY has been suggested as a treatment for cancer, and recently inhibition of ACLY has proved to be beneficial in models of high fat, high cholesterol feeding. Targeted disruption of ACLY using adeno viral shRNA-mediated knockdown resulted in decreases in VLDL TG and decreased expression of genes involved in lipogenesis and TG synthesis. In a hamster model on a high-fat high-cholesterol diet administration, an ACLY inhibitor, ETC-1002 (Bempedoic Acid), resulted in decreases in LDL and VLDL cholesterol along with decreases in hepatic CE and free cholesterol. More recent studies with Bempedoic acid showed reduced atherosclerosis progression in an Ldlr−/− mouse model, and significant increases in hepatic Abcg5/8 mRNA expression were discovered by mRNA profiling. Our studies provide a mechanism to explain the link between ACLY inhibition and increased hepatic Abcg5/8 levels, involving the short-lived transcriptional repressor PER2. This could represent an important therapeutic benefit of this approach. Although increased biliary cholesterol secretion resulting from induction of Abcg5/8 by metformin, or ACLY inhibition, might be expected to increase gallstone formation, we found that Bsep was upregulated by a similar mechanism to Abcg5/8, suggesting a coordinated mechanism to dispose of cholesterol without favoring gallstone formation. Our studies thus suggest several potential ways to link diabetes mellitus treatments with a beneficial effect on cardiovascular disease without increasing gallstone risk.

Sources of Funding
This study was supported by National Institutes of Health (NIH) grant HL107653 (A.R. Tall), and HL 87123 (A.R. Tall, D. Accili). M.M. Molusky was also supported by the T32 training grant from the NIH (HL007343) and J. Hsieh by the Gilead Sciences Liver Scholar Program. R.A. Haeusler and S.X. Lee were supported by HL125649.

Disclosures
None.

References
1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865. doi: 10.1016/S0140-6736(98)07037-8.
2. Hong J, Zhang Y, Lai S, et al; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304–1311. doi: 10.2337/dc12-0719.
3. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093–1099.
Metformin induces expression of the sterol transporters Abcg5/8 (ATP-binding cassette transporter G5/G8) by decreasing Period 2 occupancy on the Abcg5/8 promoter.

Our mechanistic data suggests a link between cholesterol excretion and hepatic lipogenic activity and circadian rhythm.

The findings suggest that both LDL (low-density lipoprotein) cholesterol lowering and increased reverse cholesterol transport could represent benefits that accrue from metformin. AMPK (5’ adenosine monophosphate-activated protein kinase) activation and ACLY inhibition via upregulation of ABCG5/8.